Neural autoantibody clusters aid diagnosis of cancer.

Autor:	Horta ES; Authors' Affiliations: Departments of Laboratory Medicine and Pathology., Lennon VA; Authors' Affiliations: Departments of Laboratory Medicine and Pathology, Neurology, Immunology, and., Lachance DH; Authors' Affiliations: Departments of Laboratory Medicine and Pathology, Neurology., Jenkins SM; Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, Minnesota., Smith CY; Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, Minnesota., McKeon A; Authors' Affiliations: Departments of Laboratory Medicine and Pathology, Neurology., Klein C; Authors' Affiliations: Departments of Laboratory Medicine and Pathology, Neurology., Pittock SJ; Authors' Affiliations: Departments of Laboratory Medicine and Pathology, Neurology, pittock.sean@mayo.edu.
Jazyk:	angličtina
Zdroj:	Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2014 Jul 15; Vol. 20 (14), pp. 3862-9. Date of Electronic Publication: 2014 May 15.
DOI:	10.1158/1078-0432.CCR-14-0652
Abstrakt:	Purpose: Clustering of neural autoantibodies in patients with paraneoplastic neurologic disorders may predict tumor type. A mathematical analysis of neural autoantibody clusters was performed in 78,889 patients undergoing evaluation for a suspected paraneoplastic autoimmune neurologic disorder. Tumor predictive autoantibody profiles were confirmed in sera from patients with histologically proven tonsillar cancer, thymoma, and lung cancer. Patients and Methods: Of note, 78,889 patient sera were tested for 15 defined neural autoantibodies (1.2 million tests). The observed and hypothesized frequencies of autoantibody clusters were compared and their tumor associations defined. A tumor validation study comprised serum from 368 patients with a variety of tumors (thymoma, lung, or tonsil). Results: Informative oncological associations included (i) thymoma in 85% of patients with muscle striational, acetylcholine receptor antibodies plus CRMP5 autoantibodies; (ii) lung carcinoma in 80% with both P/Q-type and N-type calcium channel antibodies plus SOX1-IgG; and (iii) in men, prostate carcinoma frequency more than doubled when striational and muscle AChR specificities were accompanied by ganglionic AChR antibody. In women, amphiphysin-IgG alone was associated commonly with breast carcinoma, but amphiphysin-IgG, coexisting with antineuronal nuclear autoantibody-type 1 or CRMP5-IgG, was associated with lung cancer (P < 0.0001). In the validation cohorts, many tumor-associated profiles were encountered that matched the clusters identified in the screening study (e.g., 15% of thymoma patients had striational, acetylcholine receptor antibodies plus collapsin response-mediator protein-5 autoantibodies). Conclusions: Neural autoantibodies commonly coexist in specific clusters that are identifiable by comprehensive screening. Signature autoantibody clusters may predict a patient's cancer risk and type. (©2014 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu